Start Date
2020
Status
Open to Recruitment
Principal Investigator
Dr Oliver Koch
Collaborating organisation
University of Oxford
A range of potential treatments have been suggested for pneumonia caused by influenza, community-acquired pneumonia (CAP) & COVID-19, but nobody knows if any of them will turn out to be more effective in helping people recover than the usual standard of hospital care which all patients will receive.
The RECOVERY has already shown that low doses of a type of steroid, dexamethasone, and other treatments reduce the risk of dying for some patients hospitalised with COVID-19. There are several other treatments which may turn out to be helpful (or possibly harmful) when used in the treatment of pneumonia caused by COVID-19, influenza or other organisms. This study aims to find out whether any of these additional treatments are helpful
- low-dose dexamethasone (for CAP)
- oseltamivir & baloxavir, and low-dose dexamethasone (for influenza pneumonia)
- high-dose dexamethasone & sotrovimab (for COVID pneumonia)
The COVID-19 arm of the RECOVERY trial is now closed, but the trial remains open ti CAP and flu investigations
Data from the trial are regularly reviewed so that any effective treatment can be identified quickly and made available to all patients. Please see the RECOVERY website for results that RECOVERY has already found.
Main Funding Body
